

DEDICATED TO ALLERGY SCIENCE, COMMITED TO YOUR HEALTH



Industry Report EAACI Hybrid 2023

Table of Contents





EAACI Hybrid 2023 – Scientific Programme – EAACI Sessions

- ❖ 6 Plenary Sessions
- 32 Symposia
- 7 Thematic Symposia
- ❖ 16 Interactive Workshops
- 7 Special Sessions (President Session, Opening, GA, Journals, NAS Forum, Closing,)
- 2 HOT Topics Sessions

- ❖ 8 Learning Lounges Sessions
- ❖ 6 Pro & Con Sessions
- ❖ 7 JMA Sessions
- ❖ 3 World Leaders Dialogue Sessions
- 2 Year in Review Sessions
- ❖ 8 Sister Society Sessions


												DAY 11 JUNE								TURDAY 10 JUNE SUI								
Hall 1	Hall G1	Hall 4	Hall F	Hell D	Hall Y 01+02	Hall G2	Hall E	EAACI Global Stage	Hours v	Hal	H	Hall G1	Hall 4	Hall F	Hall D	Hall Y 01+02	Hall G2	EAACI Global Stage	Hours v	Hall 1	Hall G1	Hall 4	Hall F	Hall D	Hall Y 01+02	Hall G2 H	iall E	EAACI Global Stage
									7:00										7:00									
										20										0								
									8:00										8:00	a a			EAACI General					
pediatric asthma -	responses in Allergy	development -	syndrome (HES):	YIR 1 - Year In Review 1	errors of Immunity: An	targets for	Epidemiologic Factors			20 1			SY14-Presidential	/W 6 - Blomarkers In			IW8-Impact of		9:00				00					
What is new?	and Immunotherapy			000	expanding universe	Immunomodulation	Related to allergy and	1	9:00				Symposia		Immunotherapy											ESS2 - National Allergy Society Forum:		
									10:00	. 0	0	00	00	# G B	000	00	969		10:00	and efficacy in	and allergies in children		Allergy. What is the		Impact7	Scientific highlights		
tools to endotype	Interactions over the life								10.00											. 00	00	00	000	000	60	00		
@ @ down	() (i)								11:00		for a personalised approach	Immunology							11:00									
										20	0	00							4	autoimmunity	0.0							
	year Allemy in Africa				Igint composium				12:00			SSS 4 - EAACI &							1200		00							
										20		Ø ⊕							13:00		SY 30 - EAACI Guidglines on Diagnosis		SSS 8 - EAACI & ADADARI Inint	SSS 9 - EAACI & JSA Joint symnosium: New			SY31 - New Deronantives on	PROS. Can MAT heat
and combinatory	Immune responses at	WLD 1 - Novel tools for prevention	exposure and climate	HT 1 - Climate Change	between sports and			REC 1. Are reliteren lust	13:00		V 15 - Urbonder ettil	CV 14 Innovative	WED 2 - Novel trial	TC 4 Connectedir	EWY EAACH	844		Of C 2 - Piomarkers can	4	a	00		00	00			00	
O O	00	00	000		00			PEC 2- Is specific		20	unmet needs	treatment strategies in	designs - advantages,	between nasal and	() () () () () () () () () ()	Immunomodulatory		90	14:00							SY 19 - Cutting Edge In Allermy Asthma and		Stron Challenne
				SSS 2 - EAACI & AAAAAI				(0.6)	14:00	0	6	00	00	00		00		PRC 4 - Oral	9	next-generation	syndrome (FPIES)	21st century	What's new?	00		Immunology		
occupational asthma:	Influences on allergy	responses influence	allergy in a time of	0.0	engaging with patients										Injet gumnachum Warid			0.6	15:00	00	00	00	00		00	00		
		0 B *****	00	SSS 3 - EAACI & ACAAI	O B				15:00	ar	ngloedema: Current	patient care with	Allergy Epidemic:	practical approaches in	0.0	tool in clinical trials			24.00	SY 28 - Food allergy prevention and	SY 29 - Veccine Responses during	78.6 - Atopic and contact Dermetitis:	/W 15 - Asthma exacerbations: towards			787 - Allergy to pets		1
Ovo Nevel Barrandia	CV 40 NewWester In	Circle Contan available	and Comments and	0 0	44.5 190b. of				16:00		Bornandhan	Ø B	@ B	000	SSS 6 - EAACI & SLAAI joint symposium: The	@@B			16.00	management	Biological therapies	What's new?	personalised medicine				Involving the patient	
approaches in severe	ellergic rhinitis	host versus	Management of		Molecular Allergology in supporting	1			16.00	20					fidum of allowaters				17:00	00	00	00	000			00	400	
00	00	(i) (interpretations	@ @ @	000	000				17:00		pathogenesis and	SY 21 - Epithelial barrier theory from bench to	Y/R 2 - Year In Review 2	/W11 - Update In Anaphylaxis	/W 12 - Time to stop comparing apples to	TS 5 - Immune dysregulation and		JMA 5 - Initiatives Symposium		EAACHSS 3 - Closing Caramony						71	VIVE I	
Opening ceremony and										20 M	anagement of nasal	Dedaids (i)	0.0	000	autonmon in food	primary Immunistrations of the control of the contr			18:00							0000	HVDDI	0
The second secon									18:00																/	MAN TA	HARKI	
																											1	
111111111111111111111111111111111111111	F7 - Managament of popular extension of the control of the contro	97 - Managament of popular attempt of popular attempt of popular attempt of the popular att	97 - Management of personnel of	97 - Management of personnel of	87 - Management of personnel of	87 - Management of personnel personn	97 / Annual management of post-post-post-post-post-post-post-post-	97 - Monte Disopposite approach of progression of p	97 / More designation of particular states and particular states a	D7 - Management of patients attitude and pat	D7 - Management of position starting and patients starting apparent and patients starting apparent sta	D7 - New pagement of patients attending and patients attending and patients attending and patients attending appeared attending and patients attending appeared atten	To 1. None pagement of positions arising a graduate and a graduate	107 - Novel analysis of minimum section of minimum	P7 - Novel assigned from the first and the f	17 / Nove interpretable of the first interpretab	107 - Monagement of policins rating - policins r	27. Mosagement of policy and an expension of pol	17 Most agence of process 17	## 1 September 1	## 1 Management of 1971 Manageme	File File	Triangement Triangement	1	To company To	Total services Tota		1

EAACI Hybrid 2023 – Industry Programme


- ❖ Total of 31 sponsored sessions
 - Friday 9 June 12 Satellite Symposia & 3 sponsored sessions
 - Saturday 10 June 13 Satellite Symposia & 2 Mini-Satellite Symposia
 - Sunday 11 June 1 Satellite Symposia

RIDAY 9 JUNE	S	ATURDAY 10 JUNE	SUNDAY 11 JUNE			
urs v		Hall 4	Hall F	Hall D	Hall G2	Hall E
8:00						
	30					
9:00						
	30					
10:00						
	30					
11:00						
	30					
12:00		SAT 1-3 - Stallergenes Greer - Patients'	SAT 1-4 - Blueprint Medicines - Many Faces	SAT 1-5 - Menarini - Mometasone furnate/	SAT 1-1 - Medithority CMF Sunnorted by	SAT 1-2 - Sanofi Regeneron - Clinical
	30	0 0	0 =	0 =	0 0	0 =
13:00	20				SAT 1-6 - Thermo Fisher	SAT 1-7 - GSK -
14:00					Scientific - Clinical	Redefining ambition:
14:00	20					
15:00					SAT 1-8 - Sanofi Reneneron - Tarnetinn	SAT 1-9 - Nestlé Health Science - How do HMO
10.00	30				0.0	
16:00					SAT 1-11 - Sanofi Regeneron - Pediatric	SAT 1-10 - Medthority CMF Supported by
	30				0 9	0 5
17:00					8 6	0 B
	30					
18:00					0 0	0 ⊕

RIDAY 9 JUNE	Si	ATURDAY 10 JUNE	SUNDAY 11 JUNE			
urs v		Hall 4	Hall F	Hall Y 01+02	Hall G2	Hall E
9:00						
	30					SAT 2-1 - Pfizer - Exploring the Riplany of
9:00						S S S S S S S S S S S S S S S S S S S
	30					
10:00	20					
11:00						
	30					
12:00		SAT 2-2 - AstraZenecca -	SAT 2-3 - HAL Allergy -	SAT 2-5 - Pharming -	SAT 2-6 - Sanofi	SAT 2-7 - DBV
	30	Transforming asthma	To eat or not to eat that		Renemeron	SA/ 2-/-DBV Technologies -
13:00						
	30				SAT 2-8 - ALK - Ontimision AIT clinical	SAT 2-9 - CSL Behring - Exploring new horizons:
14:00						
	30				SAT 2-10 - Allergy Therapeutics - SCIT-	SAT 2-11 - Alleronnharma - Mite -
15:00	30				00	00
16:00	20				SAT 2-12 - GSK Medical -	SAT 2-13 - AstraZenecca
10.00	20				() (E) II-5 inhibition in	The enithelial era in
17:00					SAT 2-14 - Takeda -	0 🖶
	30				Shinion a linht on unmet	
18:00						00




Overall registration statistics - Delegate numbers as of 13.6.2023





Overall registration statistics - Delegate numbers as of 13.6.2023



"On AVG an EAACI digital user spent 28 min and 43 seconds on the digital platform"


All Delegates logged in digitally

Onsite delegates that logged into digital platform





Overall registration statistics - Delegate sections as of 13.6.2023



Sections

	Overall
Basic & Clinical Immunology	1590
Asthma	1360
Allied Health & Primary Care	760
Pediatrics	911
Dermatology	451
ENT	276
Not specified*	2052

^{*} Data not specified due to delegates not logging into their MyEAACI to verify their data (mainly from group registrations)




Data may change if/when delegates verify their profile data at a later stage



Dermatology

■ Not specified

Overall registration statistics - Delegate workplace as of 13.6.2023



Type of Organisation

	Overall
University Hospital	1225
Industry	1403
Private Practice	801
Non University Hospital	628
Academic Institution	1063
Others	529
Governmental Organisation	319
Non Governmental Organisation	168
Not specified*	1264

^{*} Data not specified due to delegates not logging into their MyEAACI to verify their data (mainly from group registrations)




Data may change if/when delegates verify their profile data at a later stage



■ Not specified

Overall registration statistics - Prescribers / Non-prescribers as of 13.6.2023



Prescriber


	Overall
Yes	3681
No	2369
Not specified*	1350

^{*} Data not specified due to delegates not logging into their MyEAACI to verify their data (mainly from group registrations)










Country	Hybrid
Germany	999
Spain	525
Italy	324
United Kingdom	321
France	305
Switzerland	226
The Netherlands	183
Austria	166
Portugal	129
Ukraine	129
Poland	127
Denmark	122
Greece	97
Czech Republic	96
Sweden	93
Turkey	92
Romania	68
Belgium	62
Israel	62
Slovakia	57
Bulgaria	53

1200










Country	Digital only
United Kingdom	97
Spain	81
France	55
Germany	48
The Netherlands	43
Austria	42
Portugal	42
Poland	37
Russian Federation	36
Belgium	31
Greece	30
Italy	26
Turkey	23
Czech Republic	18
Sweden	18
Denmark	15
Ireland	15
Finland	11
Lithuania	11
Slovenia	8
Israel	7










Country	Hybrid
United States	252
Republic of Korea	77
Philippines	76
Mexico	68
China	66
Israel	62
Australia	59
Japan	57
Brazil	40
Thailand	40
Colombia	35
Canada	34
Argentina	30
Saudi Arabia	24
Taiwan	15
Hong Kong	14
United Arab Emirates	14
Singapore	13
India	13
Kazakhstan	10
Qatar	8








Country	Digital only
United States	46
Australia	27
Japan	27
China	25
Mexico	21
Brazil	17
Canada	17
Thailand	16
Saudi Arabia	14
Singapore	11
India	10
Republic of Korea	9
Hong Kong	9
Indonesia	8
Israel	7
Philippines	6
United Arab Emirates	6
Tunisia	6
Vietnam	6
Chile	5
South Africa	4






Comparative submitted abstract numbers







Abstracts statistics – Country breakdown – 1389 total late abstracts submitted




- Spain
- Germany
- Italy
- Korea, Republic of
- Portugal
- Russia
- France
- United States of America
- Tunisia
- United Kingdom
- Turkey
- Japan
- Ukraine
- Switzerland
- Austria
- Sweden
- Poland
- Denmark
- India
- China
- Israel
- Canada
- Taiwan
- Brazil
- Netherlands
- Thailand
- Hong Kong
- Belgium
- Colombia
- Greece
- Iran
-
- Ireland
- Australia
- Czech Republic
- Egypt
- Bulgaria
- Finland
- Lithuania
- North Macedonia
- Romania
- Albania
- Morocco







Abstracts statistics – Country breakdown – 1389 total late abstracts submitted




- Spain
- Germany
- Italy
- Korea, Republic of
- Portugal
- Russia
- France
- United States of America
- Tunisia
- United Kingdom
- Turkey
- Japan
- Ukraine
- Switzerland
- Austria
- Sweden
- Poland
- i olalia
- Denmark
- India
- China
- Israel
- Canada
- Taiwan
- Brazil
- Netherlands
- Thailand
- Hong Kong
- Belgium
- Colombia
- Greece
- Iran
- Ireland
- Australia
- Czech Republic
- Egypt
- Bulgaria
- Finland
- Lithuania
- North Macedonia
- Romania
- Albania
- Morocco







Abstracts statistics - Country breakdown - 432 total late abstracts submitted







Overall statistics - Industry participation / delegate interaction

Over 50
Digital
Exhibition
booths



31 Onsite Industry Symposia



1,210 views
of digital
exhibition
assets

50 Onsite Exhibiting companies (increase of 10 from 2022)



Online delegates watched on AVG 37 minutes of content across all EAACI digital channels




avg 513 unique users viewed Industry sessions in the dedicated Industry digital channels (days 1 & 2)



Top 10 Industry by onsite delegates

Top 10 Industry by both unique visits - onsite




Please note:

- Onsite data is only reported on those companies that had lead scanning devices at the entrance to their hall/room
- Metrics/data for Industry sessions are only available with booked a Premium Digital package or an <u>Additional Analytics module</u>



Digital Platform – regional delegate representation

Digital delegates regional %



TOP 5 ROW Countries – Digital delegates attendees

- 1. United States
- 2. Australia
- 3. Republic of Korea
- 4. Japan
- 5. Mexico

TOP 10 EU Countries – Digital delegates attendees


- 1. Germany
- 2. Spain
- 3. Switzerland
- 4. United Kingdom
- 5. Italy
- 6. The Netherlands
- 7. France
- 8. Austria
- 9. Portugal
- 10. Romania





Digital Platform – exhibition area

Unique users (pax) vs Total number of Views in the virtual exhibition area



Digital Exhibitors by both views – TOP 15

- 1. Allergy Therapeutics
- 2. ALK
- 3. Allergopharma
- 4. AstraZeneca
- 5. GSK
- 6. Sanofi Regeneron
- 7. HAL Allergy
- 8. Inmunotek
- 9. Novartis
- 10. CSL Behring
- 11. Stallergenes Greer
- 12. Thermo Fisher Scientific
- **13. Astria Therapeutics**
- 14. BioCryst
- 15. LETI Pharma

AVG engagement time in these digital exhibition booths (per user)

77.50 seconds





Data is from congress day 1 - subject to change to dates of reporting



Digital Platform – Unique scientific session views as of 13.6.2023

(Per day – AVG unique digital users that watched at least one session across all EAACI digital channels)







Digital/Onsite Assets – EAACI Digital Platform / Mobile App / Abstract sessions

903 AVG clicks on the EAACI Mobile App notifications per day



25min 53s
Overall time
each user spent
using EAACI
Mobile App



28min 43s
Overall time
each user spent
using the EAACI
Digital Platform

1hr 12min AVG time each user spent engaged with EAACI digital content on their PC/desktop

2124 EAACI Mobile App users / 3487 EAACI Digital platform users



EAACI Abstract Sessions

- 28 Flash Talk Sessions
- 29 Oral Abstract Session
- 3 Poster Walks 49
 Thematic Poster Sessions
- 9 JMA Poster Sessions









EAACI on Social media – Statistics LinkedIn



LinkedIn - 12,265 followers (11% increase in the last three months) Demographics:

Top job Function: Healthcare (18.7%) and Research (12.6%); Seniority level: Senior (37.3%)





Graphic 1 LinkedIn – Followers (The last 365 days)

EAACI is very well positioned in comparison to other LinkedIn pages focused on health-care and research. It has the <u>first place</u> as an organization focused on Allergy and Asthma and the second place in general.

Graphic 2 LinkedIn - Content engagement (The last 365 days)

EAACI is very well positioned as a source of scientific content in terms of the quantity and quality of its publications. We have just received the first place also in the level of engagement.







EAACI on Social media – Statistics Facebook & Twitter



Facebook- 11,390 followers





2.82 % engagement rate in Facebook (Industry Average is 1.95%) between 6 March -26 May


4.07% engagement rate in Twitter (Industry Average is 2.82%) between 6 March -26 May







4

EAACI Sponsorship Online Platform (ESOP)








- ESOP must be used by all sponsors/exhibitors allowing:
 - Easy to use ordering online
 - Dissemination of important information / specifications
 - basic reporting / sponsor income financial data for all company profiles (tab – "Ranking")
 - EAACI to monitor a list approved agencies and staff representatives on this platform
 - Follow <u>FAQ</u> for EAACI Annual congress and events important info.






4

EAACI Sponsorship Online Platform (ESOP) - continued






AACI 2020

New features


- Standardise fields to input marketing information
 - Approved company name for EAACI publications
 - Enter your company editorials / texts for EAACI publications
 - Upload the latest version of your company logo(s)
- Budget / Forecasting / Summary of revenue expenditure
 - Basic categories (i.e. each event, types of sponsor items, total spent)
 - Approval of past sponsor income required before EAACI reward points are allocated to EAACI sponsor (used to choose certain sponsor assets for the next year annual congress)
- Users (access to files & technical specifications)
 - Company representatives
 - Approved agencies (EAACI will only work with the list agencies)







EAACI Portfolio




Please make sure you are registered on this platform to recieve all releases and updates on the EAACI sponsorship items as they become available.






EAACI Sponsor tools - Metrics

EAACI Digital Congress 2023 Metrics / Data Analysis platform





- Premium Symposium Digital Package includes unique non personal delegate metrics/data provided in an easy-toread format
- For sponsors that don't purchase the premium digital package, an <u>Analytics</u> <u>additional module</u> is possible to purchase that offers the same metrics/data information
- A <u>lead retrieval module</u> is also possible to purchase additionally that will give sponsors access to the personal data of all delegates that viewed their session (GDPR compliant).



VALENCI



New congress venue/dates announcement

EAACI Congress 2024 - Valencia - Spain

Dates: 31 May - 3 June 2024





Feria Valencia







Following on from EAACI 2023


Further developments from EAACI 2023 and looking forward to EAACI 2024 Valencia:

- EAACI aims to further increase participants numbers onsite
- An increase in venue / exhibition capacity
- Further improvement in congress support services (exhibition area and session rooms)
- Further development of IT supporting services (Technology and human resources) digital upload tools, mobile app and agency support
- An exciting city location with modern and efficient venue technology
- Further assimilation of onsite and digital options throughout the annual congress
- City of Valencia and Congress Centre video <u>click here</u>



EAACI 2024

Vamos Valencia!





EAACI Hybrid 2024 – preliminary information

- Location: Valencia, Spain
- Date: 31 May 3 June 2024
- Ethical MedTech/e4ethics (CVS status): EMT34397 (Pre-clearance submitted)
- All sponsor items NOT available to book until proposed site visit in September/October 2023 (exact TBA)
- Full list of all EAACI sponsor items available here always new URL with all relevant sponsor products
- Location/venue Officially will be announced at Annual Congress in Hamburg

EAACI Meetings – ISAF 2023

Important points to note:

- Date: 5 7 October 2023
- Location: Rome, Italy
- Topic: International Severe Asthma (more information coming soon to EAACI.org here)
- Ethical MedTech/e4ethics (CVS status): EMT31067 (Provisionally Compliant)
- 5 May was the deadline for AIFA submission of company names (non Italian affiliates) for all sponsors taking part in ISAF (Italian Industry compliance process) 17 July deadline for all Italian affiliates
- List of sponsor items available <u>here</u> new URL with all relevant sponsor products
- All 2023 EAACI hybrid events <u>basic digital exhibition</u> included in the price of an onsite booth

EAACI Meetings – PAAM 2023

Important points to note:

- Location: Porto, Portugal
- Date: 2 4 November 2023
- Topic: Pediatric Allergy and Asthma (more information coming soon to EAACI.org)
- Ethical MedTech/e4ethics (CVS status): EMT32676 (Pre-clearance/in review)
- Sponsor items available NOW to book on the ESOP here (limited number of Industry sessions available –
 prelim programme with slots to be released in the coming weeks by PAAM Scientific Committee)
- List of sponsor items available <u>here</u> new URL with all relevant sponsor products
- All 2023 EAACI hybrid events <u>basic digital exhibition</u> included in the price of an onsite booth